BridgeBio Pharma BBIO Loss on Debt Extinguishment
Loss on Debt Extinguishment at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's loss on debt extinguishment.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BridgeBio Pharma's loss on debt extinguishment?
- BridgeBio Pharma (BBIO) reported loss on debt extinguishment of $0 in Q1 2026.
- How has BridgeBio Pharma's loss on debt extinguishment changed year-over-year?
- BridgeBio Pharma's loss on debt extinguishment increased by 100.0% year-over-year, from -$21.16M to $0.
- What is the long-term trend for BridgeBio Pharma's loss on debt extinguishment?
- Over 4 years (2021 to 2025), BridgeBio Pharma's loss on debt extinguishment has grown at a 58.7% compound annual growth rate (CAGR), from -$3.34M to -$21.16M.
- What does loss on debt extinguishment mean?
- The accounting loss recorded when paying off debt early.
- How do you interpret loss on debt extinguishment?
- An increase suggests the company is restructuring its balance sheet, potentially to lower future interest costs at the expense of a one-time charge.
- How does loss on debt extinguishment compare across companies?
- Occurs sporadically during debt refinancing cycles across all capital-intensive industries.